Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Bought by Brown Advisory Inc.

Brown Advisory Inc. grew its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 23.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,338,369 shares of the company's stock after buying an additional 438,057 shares during the period. Brown Advisory Inc. owned 8.35% of Establishment Labs worth $107,729,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC raised its holdings in Establishment Labs by 9,643.3% in the 3rd quarter. Barclays PLC now owns 31,471 shares of the company's stock valued at $1,362,000 after acquiring an additional 31,148 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Establishment Labs in the fourth quarter valued at approximately $12,898,000. Raymond James Financial Inc. purchased a new position in Establishment Labs during the fourth quarter worth approximately $5,494,000. KLP Kapitalforvaltning AS acquired a new position in Establishment Labs during the fourth quarter worth $161,000. Finally, Swiss National Bank grew its holdings in Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock valued at $1,774,000 after buying an additional 1,000 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $33.39 on Monday. The stock has a fifty day simple moving average of $35.67 and a 200-day simple moving average of $38.83. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. The stock has a market cap of $963.17 million, a PE ratio of -12.94 and a beta of 0.73. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $60.12.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to analysts' expectations of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Analyst Ratings Changes

ESTA has been the topic of several analyst reports. Stephens reiterated an "overweight" rating and set a $52.00 price target on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a report on Monday, April 14th. They issued a "hold" rating on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $57.40.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.